8 completed. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 8 |
Follow Fungemia: new trials by email Literature Review of Fungemia trials Research Report on Fungemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Negative Beta Glucan in ICU Patients Anidulafungin - Candidemia | Phase 4 | Completed | Universidade Federal do Rio de Janeiro | 85 | 2012-11-01 | 2019-07-08 |
| Evaluation in the Treatment of Nosocomial Sepsis Comparing Polymerase Chain Reaction With Conventional Blood Culture. Antibiotic regimen - Sepsis, Bacteremia | Phase 4 | Completed | Instituto do Coracao | 200 | 2012-01-01 | 2016-06-09 |
| Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients Anidulafungin, Fluconazole - Mycoses, Fungemia | Phase 4 | Completed | University of Pittsburgh | 200 | 2010-02-01 | 2014-12-17 |
| Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins micafungin, Micafungin, Caspofungin - Candidemia | Phase 4 | Completed | Gary E. Stein, Pharm.D. | 21 | 2008-12-01 | 2024-04-30 |
| A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects anidulafungin and voriconazole - Aspergillosis, Candidemia | Phase 4 | Completed | Pfizer | 24 | 2008-09-01 | 2010-02-09 |
| This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis Anidulafungin, Voriconazole - Candidemia, Invasive Candidiasis | Phase 4 | Completed | Pfizer | 54 | 2008-02-01 | 2011-01-17 |
| Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole) - Candidiasis | Phase 4 | Completed | Pfizer | 282 | 2007-07-01 | 2011-10-03 |
| CRITIC - Treatment of Candidemia and Invasive Candidiasis AmBisome - Candidemia, Invasive Candidiasis | Phase 4 | Completed | Gilead Sciences | 39 | 2007-05-01 | 2009-03-27 |
Candidemia (6) · Candidiasis, Invasive (3) · Mycoses (2) · Aspergillosis (1) · Bacteremia (1) · Candidiasis (1) · Central Nervous System Fungal Infections (1) · Lung Diseases, Fungal (1) · Sepsis (1)
Bacterial Infections and Mycoses (8) · Infections (8) · Inflammation (8) · Invasive Fungal Infections (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Systemic Inflammatory Response Syndrome (8) · Sepsis (7) · Mycoses (6) · Candidiasis (5) · Candidiasis, Invasive (3) · Bacterial Infections (1) · Central Nervous System Diseases (1) · Central Nervous System Infections (1)
Anidulafungin (5) · Voriconazole (3) · Fluconazole (2) · Caspofungin (1) · Micafungin (1) · liposomal amphotericin B (1)
Pfizer (3) · Gary E. Stein, Pharm.D. (1) · Gilead Sciences (1) · Instituto do Coracao (1) · Universidade Federal do Rio de Janeiro (1) · University of Pittsburgh (1)
United States (4) · Brazil (3) · Chile (1) · Colombia (1) · Italy (1) · Mexico (1) · Panama (1) · South Korea (1)
Gary E Stein, Pharm.D. (1) · Luigi Picaro (1) · Marcio Nucci, MD (1) · Nina Singh, MD (1) · Tania MV Strabelli, PhD (1)
PMID 28459966, PMID 28597967, PMID 31280481, PMID 33891293, PMID 23710653, PMID 24559321, PMID 25376267, PMID 26050015, PMID 27287231, PMID 31367384